<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886076</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000894</org_study_id>
    <nct_id>NCT04886076</nct_id>
  </id_info>
  <brief_title>Sleep Profiles in REM Sleep Behavior Disorder</brief_title>
  <official_title>Circadian Rhythms Regulation in Pre-Manifest Synucleinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder in which you act&#xD;
      out dreams during REM sleep. Sleep disturbances are very common in RBD, where they negatively&#xD;
      impact patients' quality of life and safety. One of the known causes of sleep disturbance is&#xD;
      the impairment of the &quot;circadian rhythm&quot;, or the human sleep/wake cycle. The purpose of this&#xD;
      study is to examine the role of disruption of the circadian rhythm in the development of RBD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circadian Amplitude</measure>
    <time_frame>Study Day 17-18</time_frame>
    <description>amplitude and area under the curve (AUC) of serum melatonin and clock gene expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REM Sleep Phenomena</measure>
    <time_frame>Study Day 16-17</time_frame>
    <description>REM (rapid eye movement) sleep duration, REM Index, and EMG (electromyographic) activity) assessed via overnight Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Daytime Sleepiness</measure>
    <time_frame>Study Day 17</time_frame>
    <description>MSLT (Multiple Sleep Latency Test) assessed via Polysomnography</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rapid Eye Movement Sleep Behavior Disorder</condition>
  <arm_group>
    <arm_group_label>Participants with RBD</arm_group_label>
    <description>Participants with REM Sleep Behavior Disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants without RBD</arm_group_label>
    <description>Age- and gender-matched controls, without REM Sleep Behavior Disorder</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve men and women of all ethnic groups. We will recruit adults ≥ 40&#xD;
        years of age.&#xD;
&#xD;
        Control participants will be age- (±5 years) and gender-matched to participants with RBD,&#xD;
        have no diagnosis of RBD, and meet all other inclusion/inclusion criteria as the RBD group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of RBD as assessed by the International Classification of Sleep Disorders&#xD;
             (ICDS) diagnostic criteria within 3 years&#xD;
&#xD;
          2. 40 yrs of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other significant neurological disorder&#xD;
&#xD;
          2. Untreated significant sleep apnea and/or current sleep apnea symptoms as assessed by&#xD;
             the clinical investigator&#xD;
&#xD;
          3. Co-existent restless legs syndrome (RLS), as assessed by the ICDS diagnostic criteria&#xD;
             for RLS&#xD;
&#xD;
          4. Cognitive impairment as determined by the Montreal Cognitive Assessment (MoCA) score&#xD;
             of ≤ 23&#xD;
&#xD;
          5. Presence of depression defined as the Beck Depression Inventory (BDI) score &gt;20&#xD;
&#xD;
          6. Use of tricyclic antidepressants, MAO inhibitors or selective serotonin reuptake&#xD;
             inhibitors since they may induce/worsen RBD, unless on a stable dose of medication for&#xD;
             at least 8 weeks&#xD;
&#xD;
          7. Use of medications known to affect melatonin secretion, such as lithium, α- and&#xD;
             β-adrenergic antagonists&#xD;
&#xD;
          8. Shift work, currently or within the prior 3 months&#xD;
&#xD;
          9. Travel through ≥ 2 time zones within 60 days prior to the screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksandar Videnovic, M.D.</last_name>
    <phone>(617) 724-3837</phone>
    <email>avidenovic@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Stauder, B.S.</last_name>
    <phone>(617) 726-9589</phone>
    <email>mstauder@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Stauder, B.S.</last_name>
      <phone>617-726-9589</phone>
      <email>mstauder@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Aleksandar Videnovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

